SYSTEMS, DEVICES, FORMULATIONS AND METHODS FOR CONTROLLED DRUG DELIVERY
Provided herein are systems, devices, formulations, and methods for treating a subject for treating, preventing, or ameliorating at least one symptom of a disorder, disease, or condition according to a controlled dosage regimen to provide effective treatment while reducing the risk of side effects or abuse.
1 . A drug delivery device comprising:
a) a pump mechanism configured for administering a drug formulation comprising an NMDA receptor antagonist; and
b) a user interface allowing a subject to select and self-administer a dose of the drug formulation from a selection of at least one pre-programmed dosage regimen that is not configurable by the subject;
wherein the at least one dosage regimen provides an effective drug plasma concentration.
2 . The drug delivery device of claim 1 , wherein the at least one dosage regimen provides an effective steady state drug plasma concentration.
3 . The drug delivery device of claim 1 , wherein the at least one dosage regimen is locked after configuration by an authorized user to deter modification by the subject.
4 . The drug delivery device of claim 1 , wherein the at least one dosage regimen is locked after configuration by the manufacturer to deter modification by the patient.
5 . The drug delivery device of claim 1 , wherein the drug delivery device is configured to be tamper-resistant to deter administration of a dose of the drug formulation that deviates from the at least one dosage regimen.
6 . The drug delivery device of claim 1 , wherein the drug formulation is stored in tamper-resistant cartridge.
7 . The drug delivery device of claim 1 , wherein the drug delivery device comprises a reservoir for storing the drug formulation prior to administration.
8 . The drug delivery device of claim 1 , wherein the at least one dosage regimen reduces side effects of the drug formulation while providing the state drug plasma concentration.
9 . The drug delivery device of claim 8 , wherein the side effects comprise drug dependence or addiction.
10 . The drug delivery device of claim 8 , wherein the side effects comprise hallucination, disorientation, dissociation, dizziness, drowsiness, increased heart rate, elevated blood pressure, nausea, vomiting, fatigue, brain fog, confusion, anxiety, distress, shortness of breath, or any combination thereof.
11 . The drug delivery device of claim 1 , wherein the drug delivery device is configured to administer the drug formulation according to the at least one dosage regimen for treating major depressive disorder, treatment resistant major depressive disorder, suicidality, suicidal ideation, dysthymia or persistent depressive disorder, bipolar depressive disorder type I, bipolar depressive disorder type II, chronic pain, eating disorder NOS, pain disorder NOS, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, complex regional pain syndrome, reflex sympathetic dystrophy, or any combination thereof.
12 . The drug delivery device of claim 1 , wherein the NMDA receptor antagonist is ketamine or a pharmaceutically acceptable salt thereof.
13 . The drug delivery device of claim 1 , wherein the NMDA receptor antagonist is an arylcyclohexylamine or arylcyclohexylamine derivative.
14 . The drug delivery device of claim 1 , wherein the at least one dosage regimen is configured by an authorized user who is a healthcare provider for the subject.
15 . The drug delivery device of claim 1 , wherein the at least one dosage regimen is prescribed for the subject by a healthcare provider.
16 . The drug delivery device of claim 1 , wherein the subject is not authorized to configure or modify the at least one dosage regimen.
17 . The drug delivery device of claim 1 , wherein the drug delivery device allows limited modification of the at least one dosage regimen by the subject.
18 . The drug delivery device of claim 1 , wherein the at least one dosage regimen comprises a plurality of dosing options selectable by the subject.
19 . The drug delivery device of claim 18 , wherein the plurality of dosing options is selected from the group consisting of bolus injection, continuous infusion.
20 . The drug delivery device of claim 18 , wherein the plurality of dosing options comprises differences in dosage size, dosage rate, infusion duration, or any combination thereof.
21 . The drug delivery device of claim 1 , further comprising a remote access module allowing an authorized user to remotely configure or modify the at least one dosage regimen over a network.
22 . The drug delivery device of claim 1 , further comprising a monitoring module allowing an authorized user to remotely monitor the at least one dosage regimen over a network.
23 . The drug delivery device of claim 1 , further comprising a communications module allowing the drug delivery device to pair with a communications device that provides a network connection for communicating with an authorized user.
24 . The drug delivery device of claim 1 , wherein the pump mechanism is configured to administer the drug formulation through subcutaneous or intramuscular injection.
25 . The drug delivery device of claim 1 , wherein the dose comprises an infusion rate of at least about 0.1 mg/hour.
26 . The drug delivery device of claim 1 , wherein the dosage regimen provides a clinically effective steady-state concentration of the NMDA receptor antagonist for at least 8 hours.
27 . A system comprising:
a) a drug delivery device comprising a pump mechanism for administering a drug formulation comprising an NMDA receptor antagonist and a user interface allowing a subject to self-administer a dose of the drug formulation from a selection of at least one pre-programmed dosage regimen that is not configurable by the subject; and
b) a digital device of an authorized user in communication with the drug delivery device to allow the authorized user to configure, modify, or monitor the dosage regimen;
wherein the at least one dosage regimen provides an effective steady state drug plasma concentration while reducing side effects.
28 . A method for self-treatment by a subject outside of a hospital or clinical setting, comprising:
a) obtaining a drug delivery device for administering a dose of a drug formulation comprising an NMDA receptor antagonist; and
b) self-administering the dose from a selection of at least one pre-programmed dosage regimen that is not configurable by the subject;
wherein the at least one dosage regimen provides an effective steady state drug plasma concentration while reducing side effects.
29 . A pharmaceutical composition, comprising:
(i) an NMDA receptor antagonist, or a hydrate, solvate, or pharmaceutically acceptable salt thereof; and
(ii) at least one pharmaceutically acceptable excipient,
wherein the pharmaceutical composition is in a form for dosing or administration by intravenous (I.V.), intramuscular, subcutaneous, or intradermal injection.
30 . The pharmaceutical composition of claim 29 , wherein the at least one pharmaceutically acceptable excipient is (i) a surface-active agent, (ii) a non-ionic surfactant, (iii) a phospholipid solubilization agent, (iv) a cyclodextrin excipient, (v) an emulsion stabilizer, (vi) a preservative, (vii) an antimicrobial agent, or (viii) a topical analgesic.
31 . A method for self-treatment by a subject outside of a hospital or clinical setting, comprising:
(i) obtaining a drug delivery device for administering a dose of the pharmaceutical composition of any one of claims 29 - 30 ; and
(ii) self-administering the dose from a selection of at least one pre-programmed dosage regimen that is not configurable by the subject;
wherein the at least one dosage regimen provides an effective steady state drug plasma concentration while reducing side effects.
32 . A sealed reusable delivery and control system comprising drug delivery device of any of claims 1 - 26 , wherein the drug delivery device further comprises:
a) a control system providing a multi-tiered security authentication configured to use one or more of a patient ID, physician ID, Delivery device ID, Mobile device ID, cartridge ID that is compared a database via security challenges;
b) an energy harvesting NFC tag for cartridge ID;
c) one or more accumulation registers; and
d) one or more tamper proof conductors.